$RYTM - Pharma8k's

Rhythm Pharmaceuticals (RYTM) Reports Positive Phase 2 Data for Setmelanotide in Prader-Willi Syndrome

11 Dec 2025 SEC Filing 8-K Clinical Trials $RYTM

Rhythm Pharmaceuticals (RYTM) Reports Positive Phase 2 Data for Setmelanotide in Prader-Willi Syndrome

Rhythm Pharmaceuticals (RYTM) disclosed positive preliminary results from a Phase 2 trial of setmelanotide in Prader-Willi syndrome, with BMI reductions in 6 of 8 patients.